University of Houston to install nanotech-coated air filters on campus to prevent COVID-19 spread

who's house

UH is investing in a nanotechnology developed on its own campus that can help prevent the spread of COVID-19. Photo courtesy of University of Houston

A nanotechnology developed at the University of Houston is about to make a big difference right on campus.

UH's Facilities/Construction Management Preventive Maintenance team is working on a project that will install air filters that are nanocoated with a material that was first developed at the UH Technology Bridge. UH Professor of Physics Seamus Curran has an extensive background in nanotech, and, as he learned more about COVID-19 and how it spreads, he started nano-coating facemasks to make them more resistant to the small particles that enable the spread of the virus.

Originally developed for the construction business, Curran's coating material could also be used to create hydrophobic facemasks, Curran discovered, and he founded a spin off company, Curran Biotech, to develop his next pandemic-proof innovation: nano-coated air filters.

"The big thing for me when we were shut down was that people couldn't go to work or school. The country can't live that way — but you can't send people back to work in a world that's not safe," Curran said last October in an interview for the Houston Innovators Podcast. "How do you create a safer environment? That's the thing that really got me going in the beginning in the summer. We looked at filters."

Listen to Professor Curran on the Houston Innovators Podcast:

Curran, who says he's learned more about air filters than he ever cared to, realized that even the most expensive air filters can only protect from 10 to 25 percent of viruses. And most buildings' HVAC systems would have to be replaced completely to allow for these pricier, more protective filters. But Curran Biotech's Capture Coating can be used on existing filters and HVAC systems.

Air filters coated with Curran Biotech's sealant were then tested at the New York Family Court Building, by DCAS-Energy Management Division, and now, ahead of the fall semester, UH is implementing the innovation in all buildings that have less than MERV-13 rated filters.

Curran Biotech's sealant can be used on existing air filters and HVAC systems. Photo via UH.edu

University of Houston professor and entrepreneur, Seamus Curran, has pivoted amid the pandemic to use his nanotechnology expertise to help reduce the spread of COVID-19. Photo courtesy of Integricote

Houston scientist taps nanotech in masks and air filters to use to prevent COVID-19 spread

HOUSTON INNOVATORS PODCAST EPISODE 52

For over a decade, Seamus Curran, a physics professor at the University of Houston, has worked on his nanotechnology coating substance. He first thought the innovation could be used on fabrics and textile coating, but he realized, once getting acquainted with the industry, he realized there wasn't an interest for a hydrophobic coating that could be used to prevent the spread of germs — at least, not yet.

"Like anything small startup company, one of the things you have to learn is you have to pivot — or you will die," says Curran, who had created his company Integricote (neé C-Voltaics) to take his innovation to market.

So pivot is what he did. Integricote now markets toward coating and sealing materials within the construction industry — wood, concrete, etc. — to protect from water damage and rotting. As Curran shares on this week's episode of the Houston Innovators Podcast, business was growing steadily. That is until COVID-19 hit.

His construction coating business slowed, much like the rest of business across the country, and classes at UH switched to online. Curran used this newfound time at home to dig deeper into the details of the virus, when an idea hit him.

"I learned the virus traveled in a wet medium," Curran says, "(our coating) is hydrophobic, meaning we can stop it from penetrating any fabrics."

Curran worked to create hydrophobic facemasks using his sealant, and the technology was lauded and covered by various news organizations. He created a new company under Integricote, called Curran Biotech, and he started thinking of the next pandemic-proof innovation he could create using his sealant.

"The big thing for me when we were shut down was that people couldn't go to work or school. The country can't live that way — but you can't send people back to work in a world that's not safe," Curran says. "How do you create a safer environment? That's the thing that really got me going in the beginning in the summer. We looked at filters."

Curran, learning more about air filters than he ever cared to, realized that even the most expensive air filters can only protect from 10 to 25 percent of viruses. And most buildings' HVAC systems would have to be replaced completely to allow for these pricier, more protective filters.

"So, you'd have to replace your equipment and your filter prices go up — and you're still not blocking the virus," Curran says.

Curran Biotech's solution is a spray coating that can be used on air filters to make them more protected from COVID-19 spread.

Curran shared more about his nanotechnology innovation — as well as his excitement for being named one of MassChallenge Texas's finalist within the 2020 Houston cohort — in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings